Selling into hospitals and health systems is not consumer healthcare marketing with a different landing page. The buyer is a committee, the cycle outlasts your reporting window, and the click costs more than most B2B categories. I spent five years in-house inside a large private hospital group, which means I have sat on the side that evaluates vendors like you.
Five patterns, and none of them are creative problems.
A nurse manager downloading your whitepaper cannot sign anything. In a hospital the decision runs through clinical leadership, finance, IT security, compliance and procurement, and any one of them can end it. An account optimised for form fills fills your CRM with people who are not allowed to buy.
Nine to eighteen months is normal, and capital purchases wait for the fiscal year. If you judge a campaign on a 30 day cost per lead you will switch off the thing that was working right before it produced revenue, which is the most common and most expensive mistake in this category.
Marketing reports MQLs, sales says the leads are bad, and nobody can settle the argument because opportunity stage never comes back into the ad platform. Until closed won flows back as a conversion, the algorithm is optimising for the cheapest download.
Terms in this space run from twenty dollars to well over a hundred a click. At that price a broad match keyword left unattended for a quarter is not an inefficiency, it is a line item. This is the vertical where search term discipline pays for the engagement by itself.
HCP targeting rules, health data restrictions and claims review are constraints you design around, not obstacles to route past. Campaigns built without legal in the room get paused after launch, which costs more than building them properly the first time.
Five years of senior paid media inside one of the largest private hospital groups in Latin America, covering both patient facing demand and the B2B side of the organisation, where the customer is another company rather than a patient. Figures from that work are not mine to publish and none appear here. What transfers is the part vendors rarely get access to: how a health system evaluates a supplier, which internal stakeholders can quietly stop a purchase, and why a proposal that looks strong commercially still stalls in clinical or security review. If you sell into hospitals, that is the room your marketing is trying to reach.
What changes between them is the committee and the cycle, not the method.
Long capital cycles, clinical evidence requirements and a buying committee that includes people who will physically use the device. Search demand is thin and precise, which makes waste easy to spot and easy to cut.
Shorter cycles than devices, but security review and integration questions decide the deal. Demand generation has to reach IT and compliance, not only the clinical champion who found you.
Sold on measurable operational pain, which makes the problem aware search strategy unusually effective here. The buyer already knows the number that hurts.
The most constrained of the group. Platform policy and regulatory review shape what can be said and to whom, so the work starts with what is permitted and designs backwards from there.
Health systems and provider groups with a commercial arm selling into employers or payers. B2B motion inside an organisation whose marketing team is built for patients, which is a specific and common mismatch.
Job title, function, seniority and company filters that reach clinical, IT and finance stakeholders separately, because they care about completely different things. Expensive per click and worth it when the account value justifies it, and I will tell you when it does not.
Hospitals do not search your product category, they search the problem. Readmission rates, staffing shortages, revenue cycle leakage, interoperability. Capturing that language is where the qualified pipeline hides, and it is usually cheaper than the category term everyone bids on.
CRM integration so stage changes flow back into Google and LinkedIn as offline conversions. The platform stops hunting for downloads and starts hunting for the pattern that became an opportunity. This is the single change that most often moves cost per qualified opportunity.
Target account lists running alongside category demand, so named prospects get consistent exposure while you still discover accounts you had not listed. One without the other either misses the market or ignores your own pipeline.
Assets built for a committee, not a persona. Clinical evidence, security and integration answers, and total cost framing, because those are the questions that actually stall a deal in month seven.
Pipeline contribution and cost per qualified opportunity, split by segment. Not impressions, not MQLs, and not a dashboard that needs an analyst to interpret it.
Fixed scope, agreed before we start. No percentage of ad spend, which is the model that rewards whoever persuades you to spend more.
Who signs, who blocks, how long it takes, and what your CRM can already tell us. Before touching a campaign I need to know what a real opportunity looks like in your data.
CRM to platform, offline conversions, stage definitions agreed with sales. This is the step everyone wants to skip and the one that makes the rest work.
Campaigns separated by segment and by stakeholder, with budget matched to account value rather than split evenly.
Weekly optimisation on search terms and audiences, judged on qualified opportunities. Reporting in plain language, in a format you can take into a board meeting.
The buying committee is larger and includes clinical roles who evaluate on patient outcomes rather than commercial terms, procurement is more formal, and security and compliance review can add months. It also differs from consumer healthcare marketing, which is about patient acquisition. Selling to a hospital and attracting a patient share the word healthcare and almost nothing else.
It works, and it is expensive. The targeting reaches the committee more reliably than anything else available, so it earns its cost when your average contract value is high. If your deal size is small, I will tell you that search and content will serve you better, because a hundred dollar click against a twelve thousand dollar contract rarely works out.
Measurement fixes and wasted spend cuts show inside the first month. Pipeline impact follows your actual sales cycle, so if your deals take a year, honest reporting in month three is about pipeline created and quality, not closed revenue. Anyone promising closed won inside a quarter in this category has not sold into a health system.
Yes, and it goes better when they are involved from the start rather than asked to approve at the end. Constraints on claims, targeting and data collection are inputs to the build. I have worked inside a large hospital group, so the review process is familiar rather than an obstacle.
As an independent consultant. You work with me directly, there is no account manager relaying instructions to a junior, and everything runs inside your own accounts under your ownership.
A short form beats a long discovery call. Give me the basics and I will come back with a straight read on whether I can help, usually within one business day.
Rather book a time directly? Schedule a call.